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Background. Increased expression of the glucose transporter
GLUT1 in mesangial cells (MCs) markedly stimulates glucose
transport and the formation of extracellular matrix (ECM), even
when ambient glucose concentrations are low. Certain antihyper-
glycemic agents cause GLUT1 overexpression and increase glu-
cose transport in various tissues. However, their effects on the
kidney are unknown. Because diabetic glomerulosclerosis is char-
acterized by the accumulation of mesangial matrix, we studied the
effects of antihyperglycemic agents on matrix metabolism in MCs
cultured either in 8 or 20 mM glucose.
Methods. Membrane-associated GLUT1 was measured by im-
munoblotting. The initial rate of glucose transport was deter-
mined according to the 2-deoxy-D[14C(U)]glucose uptake. Colla-
gen metabolism was studied by metabolic radiolabeling with
[14C]-proline. Fibronectin in the medium was measured by
ELISA. GLUT1 mRNA was estimated by Northern analysis.
Results. The sulfonylurea tolazamide increased GLUT1 protein
expression by 107 and 69% in 8 and 20 mM glucose-grown cells,
respectively. However, GLUT1 mRNA levels remained un-
changed. Transporter-dependent deoxyglucose uptake was in-
creased by tolazamide up to 184% in a dose-dependent fashion
and was evident at both glucose concentrations after three or five
days of exposure to the drug. Tolazamide significantly stimulated
transforming growth factor-b1 (TGF-b1) secretion and the total
synthesis of collagen and collagen and fibronectin accumulation in
the medium of MCs maintained in high or low glucose concen-
trations. The biguanide metformin did not alter GLUT1 expres-
sion, glucose transport, fibronectin formation, or collagen metab-
olism, except at high concentrations.
Conclusion. Tolazamide markedly enhances ECM synthesis and
accumulation in MCs probably by stimulating GLUT1 expression,
glucose transport and TGF-b1 secretion, irrespective of the
ambient glucose concentration. This effect was dose-dependent
and minimally inducible by metformin.
Diabetic renal disease is characterized by the progres-
sive accumulation of extracellular matrix (ECM) in the
glomerular mesangium, mesangial expansion and inexo-
rably worsening glomerulosclerosis [1, 2]. Disordered
mesangial cell (MC) synthesis and catabolism of the
components of ECM is the immediate cause for this
glomerulopathy. Numerous studies have demonstrated
that net synthesis of ECM by MCs is stimulated by
increased ambient glucose concentrations in tissue cul-
ture [3– 8], suggesting that poor glycemic control may
play an important pathogenetic role in the mesangial
matrix accumulation. The relevance of these in vitro
observations to human disease is supported by clinical
studies consistently demonstrating the beneficial effects
of normalization of plasma glucose concentrations on
the development and progression of glomerulosclerosis
[9 –14]. The effects of high glucose concentrations on
ECM formation in tissue culture are persistent and
independent of the osmotic contribution of the hexose
[6]. There is growing evidence to indicate that the
metabolism of glucose and the concurrent de novo
synthesis of diacylglycerol by MCs is necessary to elicit
changes in ECM formation [15].
In addition, there are also abundant reasons to believe
that MC autocrine activation of TGF-b mediates the
effects of high glucose concetration and utilization on ECM
metabolism [16–18], and that this growth factor is a deter-
minant in the development of human and experimental
diabetic glomerulosclerosis [19–21].
Except for the unique case of specialized epithelial cells
where glucose is concentrated by active Na1/glucose co-
transporters, this hexose enters most cells, including MCs,
by passive facilitated diffusion. In this process, specific
integral membrane proteins, the GLUT family of trans-
porters, move glucose down its concentration gradient [22].
We and others have shown that rat glomeruli in situ express
GLUTs 1, 3 and 4 [23, 24], and that GLUTs 1 and 4 are also
demonstrable in rat MCs in tissue culture [24, 25]. Due to
the presence of the insulin-responsive GLUT4, glucose
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transport in MCs may be, at least in part, insulin-regulat-
able [26]. However, the functional importance of this
transporter remains controversial [27]. GLUT1, constitu-
tively expressed and primarily located on the cell surface, is
the primary transporter responsible for basal uptake of
glucose in most cells. Recent studies have suggested that
increased glucose uptake via GLUT1 may be a major
determinant of glucose utilization and ECM formation in
MCs [25]. Indeed, the level of expression of this transporter
is directly related to the rate of synthesis and net accumu-
lation of ECM. When MCs overexpress GLUT1 protein
following viral transduction by human GLUT1 cDNA, the
resulting increase in glucose uptake and utilization is
associated with markedly enhanced net accumulation of
ECM, despite the presence of low glucose concentrations.
Interestingly, this increase in ECM exceeds even that
observed in control MCs chronically exposed to 35 mM
glucose. Because of GLUT1’s potential pivotal role in MC
glucose transport and thereby, ECM metabolism, factors
regulating the expression of this transporter may contribute
to the glomerulopathy associated with expansion of mesan-
gial matrix.
The regulation of GLUT1 expression has not been
explored in MCs, although it has been studied in non-renal
tissues in which a wide range of agents acutely and chron-
ically were shown to influence the cellular content and
activity of this transporter [28]. The oral antihyperglycemic
drugs commonly used in the treatment of type II diabetes
affect GLUT1 expression to various degrees, depending on
the tissue type and the specific agent [22]. Studies in 3T3-L1
adipocytes and L6 skeletal muscle cells have shown that
chronic exposure of these to the sulfonylureas, tolbutamide
and tolazamide, increases GLUT1 gene and protein expres-
sion. These changes were potentiated by insulin and closely
associated with enhanced glucose transport [29, 30]. Simi-
larly, in these cells and in fibroblasts, the biguanide met-
formin increased glucose transport by enhancing GLUT1
activity and/or its total cell content [31–35], and these
effects were also enhanced by insulin [31, 35, 36]. Theoret-
ically then, if the antihyperglycemics elicit similar effects in
MCs in vivo, exposure to these agents in hyperinsulinemic
forms of diabetes might potentiate MC glucose transport,
with consequent expansion of mesangial matrix.
In this study, we investigated the effects of tolazamide
and metformin on glucose uptake and ECM formation in
cultured rat MCs, utilizing drug concentrations that have
been previously demonstrated to heighten glucose trans-
port in other cell types. These two drugs were selected
because of their disparate chemical structures, metabolic
effects and pharmacokinetics. Our results demonstrate that
certain oral antihyperglycemic agents stimulate MC glucose
uptake and ECM synthesis in a manner that is independent
of the ambient glucose concentration.
METHODS
Materials
Purified rat fibronectin (Chemicon Int., Temecula, CA,
USA) was used as standard in ELISA. The polyclonal
antibody used for GLUT1 immunoblotting studies was
generated in rabbit, and specifically reacted against a 13
amino acid carboxy-terminal peptide of this transporter
isoform (East Acres Biologicals, Southbridge, MA, USA).
PAGE separations were carried out on precast 10% mini-
gels (Jule Inc., New Haven, CT, USA). An enzyme-linked
alkaline phosphatase-labeled goat anti-rabbit IgG (Or-
ganon Teknika, West Chester, PA, USA) was used in
ELISA. Neutralizing antibody to TGF-b1 (chicken anti-
human) and recombinant human TGF-b1 were obtained
from R&D Systems (Minneapolis, MN, USA). The rabbit
anti-rat fibronectin polyclonal antibody (Chemicon) used in
the ELISA did not cross-react with rat collagen I or laminin
by immunoblotting or ELISA. All MC tissue culture media
were based on a special RPMI 1640 formulation lacking
glucose, glutamine and proline, and buffered with 25 mM
Hepes (Life Technologies, Gaithersburg, MD, USA). Pro-
line L-[14C(U)] (286 mCi/mmol), proline L-[2, 3, 4, 5, -3H]
(112 Ci/mmol), hydroxyproline L-4-[3H(G)] (10 Ci/mmol),
and 2-deoxy D[14C(U)]glucose (323 mCi/mmole), were
purchased from Dupont NEN (Boston, MA, USA). The
purity of the radioisotopic internal standards used in the
quantitation of proline and hydroxyproline were estab-
lished prior to their use by chromatographic analysis (vide
infra). High purity collagenase VII (Sigma Chemical Co.,
St. Louis MO, USA) was used in the protein digestion
assays. The columns used for HPLC were 4.6 mm 3 25 cm
Ultrasphere ODS, 5 mm particle size (Beckman Instru-
ments Inc., San Ramon, CA, USA). Sodium tolazamide
and metformin hydrochloride were generous gifts from
Pharmacia Upjohn (Kalamazoo, MI, USA) and Bristol-
Myers Squibb Co. (Princeton, NJ, USA), respectively.
Tissue culture
Mesangial cells were obtained from our previously char-
acterized cloned cell line 16KC2, derived from outgrowths
of Fischer rat glomeruli [37]. These cells demonstrate a
cytoskeleton of intermediate filaments containing vimentin,
synthesize collagen types I and IV and express the Thy-1
antigen. MCs were seeded (10,000 cells/cm2) into 59 cm2 or
143 cm2 plastic dishes for metabolic radiolabeling and
GLUT1 protein measurements, respectively. Glucose up-
take was studied in 8.5 cm2 six-well plates (Corning,
Corning, NY, USA). Cells were grown in the medium
described above to which penicillin, streptomycin, 20% Nu
Serum (Collaborative Research, Bedford, MD, USA), 8
mM glucose, 2.05 mM glutamine, and an amount of proline
to provide a final concentration of 183 mM (including
proline in Nu Serum), was added. The inclusion of Nu
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Serum provided a final concentration of 4 mg/ml insulin. In
studies in which the effects of high glucose concentration
were investigated, cells were maintained in a 20 mM glu-
cose-containing medium for 12 to 14 days before the
experiments. Considering the high concentrations of glu-
cose that commonly occur in the diabetic milieu (20 to 30
mM), a glucose concentration of 8 mM was considered as
“normal.” Indeed, lower concentrations of glucose do not
support robust MC growth [3]. All experiments were ter-
minated seven days post-seeding when cultures had just
reached confluence.
Northern analysis
We used a modified standard method, obtaining total
RNA from MC cultures with RNA Stat-60 (Tel-Test Inc.,
Friendswood, TX, USA) [25]. Twenty microgram-samples
of total RNA were glyoxalated and fractionated on 1%
agarose gels made in 10 mM sodium phosphate buffer.
RNAs were immobilized on Genescreen membranes (Du-
pont NEN), prehybridized and probed with random oli-
gomer-primed cDNAs of GLUT1 and b-tubulin in the
presence of [a-32P]dCTP (PRIME-1 kit; Sigma Chemical
Co.). Following autoradiography at 270°C, films were
analyzed by optical scanning densitometry (Scan Master
31; Howtek Inc., Hudson NH, USA) using the NIH Image
v. 1.6 software (Natl. Technical Information Service,
Springfield, VA, USA). Relative quantities of GLUT1
mRNA in treated and control cells were normalized to
their corresponding signal intensities for b-tubulin.
Immunoblotting of membrane-associated GLUT1
Cell layers were washed with ice-cold PBS and scraped
into a 20 mM Hepes buffer, pH 7.4, containing 250 mM
sucrose, 2 mM EDTA, 5 mM sodium azide, 0.2 mM phenyl-
methylsulfonyl fluoride, 1 mM pepstatin and 1 mM leupeptin.
After homogenization in a Potter-Elvehjem tissue grinder,
samples were centrifuged at 760 3 g for 10 minutes to
remove nuclei and unbroken cells. The resulting superna-
tant was centrifuged again at 142,000 3 g for 60 minutes to
obtain total cellular membrane particulates [38]. The mem-
brane pellet was resuspended in 0.9 ml of 0.01 M Tris buffer,
pH 7.5, containing 4 mM EDTA, and solubilized at room
temperature for 30 minutes by the addition of 0.1 ml 10%
(wt/vol) SDS. The solution was centrifuged at 10,000 3 g
for 10 minutes and an aliquot removed for protein quanti-
tation. Immunoblotting analysis was carried out according
to methods previously described for the study of GLUT1
[39]. Duplicate samples of 20 and 30 mg quantities of
membrane protein were incubated for 30 minutes in 2%
SDS Laemmli sample buffer at room temperature. After
separation by SDS-PAGE, proteins were electrophoreti-
cally transferred to Hybond-ECL nitrocellulose mem-
branes (Amersham Life Sciences, Arlington Heights, IL,
USA). The primary antibody, polyclonal rabbit anti-
GLUT1, was dissolved in 0.1 M Tris-buffered 0.9% NaCl
containing 5% non-fat dry milk and incubated with the
nitrocellulose membranes at 4°C for 18 hours. The second-
ary antibody, a horseradish peroxidase anti-rabbit-Ig con-
jugate (Amersham) was used in a chemiluminescence-
based detection system based on the Luminoly reaction
(ECL Western blot kit; Amersham). The identification of
GLUT1 bands was confirmed by preadsorption of anti-
GLUT1 antiserum with 25 mg/ml of purified peptide.
Quantitative analyses of the protein bands were carried out
by optical scanning densitometry, as described above. All
samples were analyzed in quadruplicate and the mean
value of data at the two levels of electrophoresed mem-
brane protein was considered as the final result.
Production of extracellular matrix components,
metabolic radiolabeling and enzyme-linked
immunosorbent assay
The metabolism of total collagen was studied as previ-
ously described [25, 40]. In brief, the culture medium was
changed 24 hours before the start of the radiolabeling
period to a medium lacking proline. Radiolabeling was
carried out by incubation for 72 hours in an identical
medium that also contained 0.15 mM b-aminopropionitrile,
210 mM ascorbic acid and 183 mM [14C]-proline (82.3
mCi/mmole). In previous experiments we had demon-
strated that [14C]-proline incorporation into collagen in-
creases linearly during 72 hours of radiolabeling [40]. At
the termination of radiolabeling, the medium was rapidly
aspirated, the plate placed on ice, and then 2 to 6 ml of
ice-cold 0.2 N perchloric acid was poured onto the cell layer.
Total protein in media samples was precipitated in 75%
ethanol at 25°C. Following the addition of 89 mCi [3H]-
proline as an internal standard, supernatants were filtered
in Centricony-3 filters (Amicon Co., Danvers, MA, USA)
and amino acids separated by solid phase extraction using
Poly-Prep® AG50W-X8 (H1) columns (Bio Rad Labora-
tories, Hercules, CA, USA). Purified amino acids were
resuspended in 0.1 N HCl for subsequent determination of
[14C]-hydroxyproline, [14C]-proline, total proline, and the
calculation of proline specific radioactivity.
Net collagen accumulation in the medium was estimated
by two independent methods that have been previously
described in detail [25]. In the first, the rate of net collagen
accumulation was measured according to 14C incorporation
into protein-associated hydroxyproline. In addition, quan-
titation of catabolic rates was also carried out in the same
sample by determining 14C incorporation into newly
formed free hydroxyproline in the medium. The validity of
these measurements of collagen metabolism has been well
established [41, 42]. After cold ethanol precipitation, pro-
teins were hydrolyzed and amino acids separated, as above,
by solid phase extraction after the addition of 3.32 mCi
[3H]-hydroxyproline as an internal standard. These purified
amino acids were subsequently analyzed for measurement
of 14C incorporation into hydroxyproline. In the second
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method, the amount of total 14C incorporated into collag-
enase-digestible protein was determined [43]. Following
completion of metabolic radiolabeling, an aliquot of me-
dium was mixed with a proteinase inhibitor solution (pro-
viding per milliliter: 3 mmole PMSF, 0.1 mmole EDTA, 40
mmole N-ethylmaleimide). Proteins were precipitated with
ice-cold 10% TCA, and the pellet was extensively washed
and resuspended in 1 N NaOH. After neutralization and
adjusting the pH to 7.5 with 1 N Tris buffer solution, PMSF
and N-ethylmaleimide were added in the same amounts as
before, and CaCl2 was added to provide a final concentra-
tion of 5 mM. For enzymatic digestion, the sample was
divided into two equal portions and 140 U/ml of collage-
nase added to one of them while the other was used as a
control. After incubation, the undigested protein was re-
moved by precipitation and the 14C radioactivities in the
supernatants and protein precipitates were measured. Re-
spective radiolabel incorporation into collagenase-digest-
ible and collagenase-resistant protein was determined from
the difference between treated and non-treated samples.
To measure total collagen deposited in the cell layer,
immediately after addition of cold 0.2 N perchloric acid, the
cell layer was scraped, briefly homogenized in the cold and
the precipitate separated by centrifugation. This precipitate
was then, lipid-extracted and consecutively subjected to
alkaline and acid hydrolysis for the measurement of total
RNA, DNA [44] and the separation of protein. The final
protein precipitate was hydrolyzed as described above,
[3H]-hydroxyproline internal standard added, and amino
acids purified and separated for the quantitation of 14C
incorporation into proline and hydroxyproline as described
for the medium protein.
Amino acids were analyzed as their precolumn-dansy-
lated derivatives by reverse-phase high pressure liquid
chromatography (HPLC) [40]. The column effluent was
monitored for fluorescence (Spectroflow 980 fluorescence
detector; Applied Biosystems, Ramsey, NJ, USA) at 350
nm excitation and 470 nm emission wavelengths, and 0.3 ml
fractions were collected for measurement of 3H and 14C
content. The recoveries of [3H]-labeled proline and hy-
droxyproline were 43 to 77% and 70 to 96%, respectively.
The fibronectin that had accumulated in the culture
medium was quantified by ELISA, using a procedure
previously described [25], except that the Nu Serum con-
tained in the medium was not removed. The amount of
fibronectin-reacting material detected in the Nu Serum
used for tissue culture was subtracted from all samples.
2-Deoxyglucose transport
The initial rate of glucose transport was determined,
according to a modification of the method of Bashan et al,
by using the non-metabolizable analog, 2-deoxy-D-glucose
[45]. MC layers were rinsed and incubated for 10 minutes in
a medium similar to that used for cell growth, but lacking
glucose and Nu Serum (thus, without insulin) and contain-
ing 10 mg/ml BSA. After removal of the medium and
washing the cell layers with 1 mg/ml BSA in Dulbecco’s
buffer (Gibco 14040-206; Life Technologies) at room tem-
perature, cultures were incubated for three minutes in 1.5
ml/well of a solution containing a total of 10 mM 2-deoxy-
D-glucose and 1 mCi/ml of 2-deoxy-D[14C(U)]glucose in
Dulbecco’s buffer. Incubations were terminated by the
addition of 1.5 ml ice-cold PBS containing 0.3 mM phloretin
and 20 mM unlabeled 2-deoxy-D-glucose, and the rapid
removal of the incubation solution from the culture well.
After rapidly rinsing cultures three times with this solution,
1 N NaOH was added to the wells for incubation at room
temperature for 60 minutes with gentle agitation to remove
cell layers. This was followed by the transfer of the pooled
contents of two wells to form one sample and completion of
the protein digestion by an additional 60 minute incubation
at 80°C. A portion of this final solution was used for
measurement of protein and the remainder used for the
determination of 14C content. The amount of extracellular
radioactivity present in the sample and the transporter-
independent glucose uptake were determined in parallel
culture wells in which rinsing with BSA-Dulbecco’s buffer
and incubation with radiolabeled 2-deoxyglucose were car-
ried out in the presence of 10 mM of cytochalasin B, an
inhibitor of glucose transporters.
Transforming growth factor-b bioassay
The production of bioactive TGF-b from mesangial cells
was determined in a mink lung epithelial cell responder
line, stably transfected with the human plasminogen acti-
vator inhibitor (PAI-1) gene fused to a luciferase reporter
gene (kindly provided by Dr. D.B. Rifkin, New York
University, New York, NY, USA). The promoter is respon-
sive to active TGF-b. The assay was carried out as de-
scribed by Abe et al [46]. In brief, transfected mink lung
cells were seeded in a 96-well tissue culture dish (1.8 3
104/well) and allowed to attach for three hours at 37°C in a
5% CO2 incubator. The medium was then replaced with
100 ml of test sample. Samples, both untreated for active
TGF-b, and heat treated (80°C for 10 min) for total TGF-b
(latent plus active), were used. Following overnight incu-
bation at 37°C, the cells were washed twice with phosphate-
buffered saline and extracted with 100 ml of lysis buffer
(Promega, Madison, WI, USA). Twenty microliters of the
lysate was transferred to a test tube and analyzed using a
Optocomp 1 Luminometer (MGM Instruments Inc., Ham-
den, CT, USA) with 100 ml injections of luciferase reagents
(Promega, kit E1500). Specificity was determined by the
ability of TGF-b1 antibodies (R&D Systems) to block
luciferase stimulation. All samples were analyzed in tripli-
cate. Concentrations were determined from a standard
curve, generated in each experiment using recombinant
TGF-b1 (R&D Systems), and expressed as picograms per
microgram of DNA.
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Chemical measurements
Protein was measured by the method of Lowry using
BSA as the standard. RNA was measured by the orcinol
reaction for quantitation of its ribose content. In this
method 1 mg of yeast RNA is equivalent to 0.6 mg of ribose
[47]. DNA was measured spectrophotometrically by a
two-wavelength ratio method [48] using calf-thymus DNA
(Type I; Sigma Chemical Co.) as the reference standard. To
calculate the amount of dansyl to be used in amino acid
derivatization, total amino acids were quantified by a
modified ninhydrin method [49], using L-leucine as the
standard.
Expression of results and statistical analyses
Results of radiolabel incorporation, adjusted for internal
standard recovery, were corrected for the specific radioac-
tivity of the medium’s proline, at the end of the incubation
period, and expressed as nmole proline incorporated per
milligram DNA. We previously demonstrated that calcula-
tion of the results of radiolabel incorporation according to
the specific activity of proline in the endogenous pool or in
the incubation media does not alter the differences be-
tween experimental groups, because changes in the endog-
enous pool of proline closely mirror those in the medium
[40]. Net collagen accumulation in the culture medium was
expressed as the proline incorporated into protein-associ-
ated hydroxyproline. In the alternate method, net collagen
accumulation in the medium was measured as the total 14C
radioactivity incorporated into collagenase-digestible pro-
tein. Collagen catabolism was calculated as the amount of
proline incorporated into newly formed free hydroxypro-
line in the medium. Total collagen synthesis was taken as
the sum of the amounts of proline incorporated into all
forms of hydroxyproline (medium free hydroxyproline and
protein-associated hydroxyproline). Depending on the type
of experiment, results were expressed as per unit protein in
the cell layer, or as per unit DNA. With the methods
utilized, the cellular content of DNA was 27.4 6 1.74 pg.
The densities of the bands in the immunoblotting and
Northern analyses were expressed in arbitrary optical den-
sity units, and the final results presented as percent change
from control values.
Statistical analyses were carried out using StatView® 4.0
software (Abacus Concepts Inc., Berkeley, CA, USA).
Results were expressed as mean 6 SEM. Differences be-
tween two groups were evaluated by Student’s t-test for
non-paired samples and the distribution of t in a two-tailed
test. Results from experiments involving multiple groups
were analyzed by analysis of variance. If a significant
difference was found among groups, between group com-
parisons were made with post-hoc testing by a Fisher’s
protected least significant difference test. Statistical signif-
icance was set at the 5% level.
RESULTS
Expression of GLUT1 protein and GLUT1 mRNA
To investigate the influence of antihyperglycemic agents
on the steady-state MC expression of membrane-associated
GLUT1 transporters, the effects of a five-day exposure to
tolazamide or metformin were evaluated. In addition, since
the extracellular concentration of glucose could modify the
action of these drugs, experiments were also carried out in
cells cultured in media containing different glucose concen-
trations.
Compared to control MCs incubated in 8 mM glucose,
prolonged exposure to a 20 mM concentration only caused
a moderate, nonsignificant decrease in membrane-associ-
ated GLUT1 protein (Fig. 1). The presence of tolazamide
resulted in a marked increase in GLUT1 that, upon com-
parison to the corresponding controls, was greater in 8 mM
than in 20 mM glucose (107% vs. 69%, P 5 0.015; Fig. 1).
However, exposure to metformin at two different concen-
trations did not increase GLUT1 protein expression,
whether MCs where incubated in 8 or 20 mM glucose (Fig.
2).
The level of GLUT1 mRNA was unaltered at the end of
a two or five day period of tolazamide treatment in either
8 or 20 mM glucose, utilizing experimental conditions
identical to those in which GLUT1 protein expression was
elevated (Fig. 3).
Deoxyglucose transport
To determine whether the chronic changes in GLUT1
protein expression induced by tolazamide were also asso-
ciated with increased glucose transporter activity, the initial
rate (3 min) of 2-deoxyglucose uptake was determined in
MCs previously treated for five days with increasing con-
centrations of tolazamide or metformin. Preliminary exper-
iments had demonstrated that 2-deoxyglucose uptake in-
creased linearly with time, at least for the initial five
minutes of incubation. Tolazamide significantly increased
2-deoxyglucose transport by 184% over control values in a
concentration-dependent manner (Fig. 4). Furthermore,
the majority of this enhanced transport was due to the
activity of GLUT transporters, as exemplified by the nearly
complete suppression of the increased uptake in the pres-
ence of cytochalasin B. In contrast to tolazamide, met-
formin increased 2-deoxyglucose uptake only modestly
(50%) and then, only at 500 mM, the highest concentration
tested (Fig. 4). MCs chronically maintained in 20 mM
glucose demonstrated a 46% greater transport of 2-deoxy-
glucose than cells grown in 8 mM glucose medium. Further-
more, tolazamide significantly increased glucose transport
by 65 to 175% over control at either glucose concentration.
This effect was maintained even after three and five days of
exposure to the agent (Fig. 5). The effect of metformin on
2-deoxyglucose uptake by cells maintained in 20 mM glu-
cose was essentially the same as for cells cultured in 8 mM
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glucose. That is, only at a concentration of 500 mM met-
formin was there a significant increase in uptake of 30% (20
mM glucose, Control, 34.0 6 1.4; 0.05 mM metformin,
39.3 6 1.4, P 5 0.52; 0.5 mM metformin, 44.3 6 2.4, pmole
2-deoxyglucose/mg protein/min, P , 0.001, N 5 8 in all
groups).
Production of extracellular matrix components
To analyze in detail how collagen metabolism might be
altered by tolazamide or metformin, the synthesis and
catabolism of collagen was studied in MCs cultured in
media containing 8 or 20 mM glucose. The three day
accumulation of collagenous protein and newly-formed
free hydroxyproline in the medium was determined during
the last three days of a total five-day exposure to the drugs.
MCs exposed to 20 mM glucose demonstrated a 41%
increase in collagen synthesis as compared to cells main-
tained in 8 mM glucose (Fig. 6). Although this enhancement
of synthesis was also associated with a significant increase
in the catabolic rate, the preponderance of the former
resulted in a net 41% increase in the amount of collagen
that had accumulated in the medium by the end of incuba-
tion. The presence of tolazamide caused a significant 40 to
42% stimulation of the collagen synthetic rate in MCs
incubated in either 8 or 20 mM glucose (Fig. 6). In 8 mM
glucose-incubated cells, this stimulation increased the syn-
thetic rate to levels similar to those of non-treated MCs
exposed to 20 mM glucose. Because this tolazamide-stimu-
lated synthesis was associated only with small changes in
catabolism (Fig. 6), the percentage of newly formed colla-
gen catabolized by tolazamide-treated cells was signifi-
cantly less than in controls (8 mM glucose, control, 44.8 6
1.2%, N 5 6; 8 mM glucose, tolazamide, 37.7 6 0.4%, N 5
6, P , 0.0001; 20 mM glucose, control, 44.9 6 1.2%, N 5 6;
20 mM glucose, tolazamide, 38.8 6 1.2%, N 5 6, P 5
0.0002). As a consequence of this imbalance, treatment
with tolazamide produced a marked net accumulation of
collagen in the medium. The increments above control
were 60% and 54% in 8 and 20 mM glucose, respectively
(Fig. 6). Measurement of collagen accumulation at the end
of incubation by another method, proline incorporation
into the medium’s collagenase-sensitive protein, yielded
virtually identical results (8 mM glucose, control, 56.2 6
13.6, N 5 6; 8 mM glucose, tolazamide, 110.9 6 19.5, N 5
5, P 5 0.024; 20 mM glucose, control, 153.5 6 7.6, N 5 6; 20
Fig. 1. Membrane-associated GLUT1 expression in mesangial cells
treated with tolazamide. Mesangial cells in tissue culture were continu-
ously grown in 8 mM glucose medium or maintained for a total of 13 to 14
days before termination of the experiment in 20 mM glucose medium. Cell
layers were collected seven days post-seeding. Experimental groups were
incubated with 1.5 mM tolazamide during the last 72 hours. Representative
immunoblots of duplicate analyses of 20 mg cell membrane protein are
presented (top) for each experimental group: (a), 8 mM glucose; (b), 8 mM
glucose 1 tolazamide; (c), 20 mM glucose; (d), 20 mM glucose 1
tolazamide. A 2 mg protein sample of human erythrocyte membrane
protein was included as a positive control (e). The final data presented
(bottom) are the combined results obtained in three separate experiments.
The number of samples is indicated, each sample having originated from
the pooling of the cell membranes obtained from five culture dishes. Each
individual sample was analyzed in quadruplicate and the mean taken as
the final value. Results are expressed as percent change from 8 mM glucose
control values. Values are mean 6 SEM. *P , 0.001 versus 8 mM control;
‡P 5 0.022 versus 20 mM control.
Fig. 2. Membrane-associated GLUT1 expression in mesangial cells
treated with metformin. Mesangial cells in tissue culture were exposed to
the concentrations of metformin noted under conditions identical to those
in Figure 1. The data presented are the mean value of two samples
generated in two separate experiments, each sample having originated
from the pooling of the contents of five culture dishes.
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mM glucose, tolazamide, 277.0 6 19.1 nmole proline/mg
DNA, N 5 6, P , 0.0001).
Although the quantity of collagen deposited in the cell
layer was only a small fraction of that accumulated in the
medium (8 mM glucose-incubated cells, 6.1 6 0.2%), the
effects of high glucose and tolazamide were also evident in
the cell layer, albeit the differences between groups were of
lesser magnitude. The increase in the medium accumula-
tion of collagen induced by 20 mM glucose did not achieve
statistical significance (8 mM glucose, 3.34 6 0.18, N 5 5; 20
mM glucose, 3.79 6 0.18, nmole proline/mg DNA, N 5 5,
P 5 0.201). However, treatment with two different concen-
trations of tolazamide significantly increased collagen dep-
osition over the levels shown in 20 mM glucose-incubated
cells (1 mM tolazamide, 4.64 6 0.45, N 5 4, P 5 0.003; 1.5
mM tolazamide, 4.30 6 0.15 nmole proline/mg DNA, N 5
4, P 5 0.018).
The effect of tolazamide on cell growth was defined in
terms of induced change in the RNA/DNA ratio. MCs
incubated in a high glucose concentration demonstrated
significant cellular hypertrophy (8 mM control, 219 6 5,
N 5 6; 20 mM control, 254 6 5, N 5 6, P 5 0.0008). In
addition, exposure to 1.5 mM tolazamide further increased
cell hypertrophy in both 8 (282 6 9, N 5 6, P , 0.0001) and
20 mM glucose (337 6 4, N 5 6, P , 0.0001).
The effect of metformin on MC collagen metabolism was
studied utilizing the same experimental conditions as those
described for tolazamide. MCs, cultured in 8 mM glucose
and exposed to 200 mM metformin over a five-day period,
did not demonstrate a change in the synthetic or catabolic
rates, nor in the net accumulation of collagen in the
medium (Fig. 7). In addition, this drug did not influence
cell hypertrophy (RNA/DNA, control, 181 6 15, N 5 8;
metformin, 178 6 7, N 5 8, P 5 0.31). Because the
metabolic effects of metformin may be only evident in cells
incubated in a high glucose concentration [33], the net
accumulation of total collagen in the medium was also
explored in MCs grown in 20 mM glucose. Metformin, at
either 200 or 500 mM concentrations, did not alter total
collagen accumulation in the medium (Fig. 8). Further-
more, these results were confirmed by measurement of
collagen accumulation according to the quantity of collag-
enase-sensitive protein in the medium (data not shown).
The effects of tolazamide and metformin on the synthesis
of other ECM components were also studied by measuring
fibronectin concentration in the medium at the completion
of the same experiments above. As anticipated, the 72 hour
accumulation of fibronectin in the medium was higher in
control cultures containing 20 mM glucose than in cultures
containing 8 mM glucose (Fig. 9). As demonstrated for total
collagen, the addition of 1.5 mM tolazamide to the 8 mM
glucose medium induced an increase in fibronectin accu-
mulation that clearly exceeded the enhancement resulting
from a high glucose concentration alone (Fig. 9). Corre-
spondingly, the inclusion of tolazamide in the 20 mM
glucose containing medium also induced a further incre-
ment in fibronectin accumulation (88% greater than in 20
mM controls), exceeding by 2.5-fold that quantity observed
in 8 mM glucose controls (Fig. 9). In contrast to the effects
of tolazamide, metformin only caused a 23% increase in
fibronectin accumulation in cells that had been incubated
in 20 mM glucose and this, as shown before for 2-deoxyglu-
cose uptake, was only evident at a concentration of 500 mM
(Fig. 8).
Finally, the dose-response relationship of the tolaz-
amide-induced increment of ECM accumulation was stud-
ied also in MCs maintained in 8 mM glucose and exposed
for five days to tolazamide in concentrations ranging from
0.1 to 1.5 mM. As shown in Figure 10, fibronectin and total
collagen accumulated in the medium in parallel and in a
Fig. 3. Effects of tolazamide on mesangial cell GLUT1 mRNA level. Cells
were grown in media with two different glucose concentrations and
exposed to 1.5 mM tolazamide as in Figure 1. Total RNA was isolated for
Northern analyses where GLUT1 mRNA appeared at 3.0 Kb. The
autoradiograms were analyzed by optical scanning densitometry and
values expressed as arbitrary units. All samples were analyzed in duplicate
with normalization of the results according to the corresponding transcript
levels for the housekeeping b-tubulin gene. The results presented are
relative quantities of GLUT1 mRNA in treated and 20 mM glucose-
incubated cells, with 8 mM glucose-incubated cells as a reference. Each
value represents the mean 6 SEM of three samples obtained in separate
experiments. Each sample originated from the pooling of the contents of
six culture dishes. A representative example of a pair of autoradiograms
from the same sample is presented in panel A (GLUT1) and B (b-tubulin)
in which duplicates corresponding to 8 mM glucose [1, 2], 8 mM glucose 1
tolazamide [3, 4], 20 mM glucose [5, 6], and 20 mM glucose 1 tolazamide
incubated cells [7, 8] are shown.
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dose-dependent fashion, achieving maximal values at a
tolazamide concentration of 1 mM.
TGF-b1 activity
To investigate whether the tolazamide-induced increase
in glucose transport could have triggered enhanced auto-
crine TGF-b1 activity, even in circumstances of low glucose
concentrations, the secretion of total TGF-b1 into the
medium and its activation were determined in MCs contin-
uously grown in 8 mM glucose following exposure to
tolazamide. After five days of incubation in the presence of
1.5 mM tolazamide, the 24-hour secretion of total TGF-b1
(active and latent) and the medium concentration of the
active form of TGF-b1 were increased by 95% and 94%,
respectively (Fig. 11). Therefore, under identical experi-
mental conditions, it was demonstrated that the long-term
exposure of MCs to tolazamide induces a concomitant
increase in glucose transport, TGF-b1 activity and ECM
accumulation (Figs. 4, 6, 9 and 11).
DISCUSSION
Sulfonylureas, including tolbutamide, tolazamide, glipiz-
ide, glibenclamide and glimeperide are known to stimulate
glucose transport in myocytes and adipocytes in tissue
culture. This effect is persistent, concentration-dependent
and demonstrable at drug concentrations within the thera-
peutic range [29, 30, 50–55]. Sulfonylureas stimulate the
cellular uptake of glucose by potentiating the effect of
insulin, however, they may also enhance the hexose’s
transport even in the absence of insulin [30, 53, 56]. The
mechanism by which sulfonylureas alter glucose uptake has
been attributed, in part, to increased GLUT1 activity [30,
55, 56]. In contrast to GLUT4, GLUT1 is located primarily
at the cell surface [57] and demonstrates a lesser degree of
cytosolic to membrane translocation following insulin stim-
ulation. Thus, GLUT1 is generally considered hormonally
insensitive [58]. However, under certain circumstances,
such as exposure to stressful stimuli, augmentation of
glucose transport can be accounted for by GLUT1 translo-
cation from an intracellular pool to the plasma membrane
Fig. 4. Effects of metformin and tolazamide on
mesangial cell 2-deoxyglucose uptake. All
studies were carried out on cells continuously
grown in 8 mM glucose and treated under
conditions identical to those in Figure 1.
Studies were carried out in cultures
preincubated in a glucose-free buffer solution
prior to the addition of 2-deoxy-D-[1-
3H]glucose. The results presented, including
those for the 1.5 mM tolazamide/cytochalasin
group, are values obtained after subtraction of
the uptake in control cells treated with 10 mM
cytochalasin (7.30 6 0.88 pmol/mg protein/min,
N 5 12). Results are presented as the mean 6
SEM, in control (N 5 14) and in experimental
groups (N 5 4 to 8). *P , 0.001 versus control.
Fig. 5. Influence of medium glucose concentration and duration of
exposure to tolazamide on the uptake of 2-deoxyglucose uptake by
mesangial cells. Cells were grown in different concentrations of glucose as
in Figure 1 and treated with 1.5 mM tolazamide during the last three or five
days of the experiments. Measurements of the rate of 2-deoxyglucose
uptake were carried out as in Figure 4. Results are presented as the
mean 6 SEM, N 5 8 in all groups. *P , 0.001 versus 8 mM control; ‡P ,
0.001 versus 20 mM control.
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[59]. Conversely, increased cell GLUT1 content, in re-
sponse to either inhibition of oxidative phosphorylation or
exposure to calcium ionophore, has been attributed to
enhanced gene transcription of GLUT1 and specific stabi-
lization of its message [60, 61]. In adipocytes and myocytes,
sulfonylureas have been shown to effectively increase
GLUT1 expression and promote its membrane transloca-
tion [30, 56, 62]. Tolazamide specifically increases GLUT1
protein in a dose-dependent fashion at 0.3 to 1.8 mM
concentrations in L6 skeletal muscle cells [29]. This effect is
associated with increased levels of GLUT1 mRNA and is
cycloheximide-inhibitable, implying that there is a stimu-
lated synthesis of the transporter, rather than augmentation
of its intrinsic activity [29].
Our study demonstrates that tolazamide concentrations
between 0.1 and 1.5 mM increase glucose transport in MCs.
In addition, the enhanced transport is equally evident in
cells cultured in media containing either 8 or 20 mM
glucose. This effect of tolazamide is sustained over pro-
longed periods and is equally prominent following three or
five days of exposure to the drug. Because this change is
inhibited by cytochalasin B and is also accompanied with
increased membrane-associated GLUT1, the effect of to-
lazamide is most likely mediated through augmented trans-
porter activity. Notably, the increase in GLUT1 protein
induced by tolazamide, as with glucose transport, is simi-
larly demonstrable after prolonged exposure to the agent
and evident in cells grown at widely different glucose
concentrations. In contrast to other cell types, the increased
amount of transporter in MCs is not associated with altered
steady-state levels of GLUT1 mRNA, suggesting that sta-
bilization of GLUT1 transcripts or a decrease in catabolic
rate of the GLUT1 protein may be responsible for this
change [63]. Nevertheless, an enhanced membrane trans-
location, without an associated increase in transporter
Fig. 6. Effects of medium glucose
concentration and exposure to tolazamide on
mesangial cell collagen metabolism. Mesangial
cells were incubated in media containing two
different glucose concentrations with and
without the addition of 1.5 mM tolazamide as in
Figure 1. Metabolic radiolabeling with [14C]-
proline was carried out during the last 72 hours
of the experiment. Collagen catabolism and
accumulation were measured according to the
amount of proline incorporated into the
medium’s newly formed free hydroxyproline
and protein-associated hydroxyproline,
respectively. Total collagen synthesis was
calculated from the sum of the amounts
catabolized and accumulated. Each value
represents the mean 6 SEM of six samples.
*P , 0.001 versus corresponding 8 or 20 mM
untreated control; ‡P , 0.001 versus 8 mM
control; §P 5 0.01 versus 20 mM control.
Symbols are: (M, u) control; (o,   ) 1.5 mM 1.5
mM tolazamide.
Fig. 7. Effects of metformin on mesangial cell collagen metabolism.
Collagen metabolism was studied in the presence of 200 mM metformin in
the medium following methods identical to those in Figure 6, except that
all cultures were carried out in 8 mM glucose. Values are mean 6 SEM, N 5
6. Symbols are: (M) control; (   ) 200 mM metformin.
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synthesis cannot be totally ruled out. In addition, tolaz-
amide may have also enhanced the expresion and/or mem-
brane translocation of GLUT4, as it has been described in
cardiomyocytes and adipocytes exposed to the sulfonylurea,
glimepiride [62, 64]. This could explain why cells incubated
in 20 mM glucose and treated with 1.5 mM tolazamide
synthesize more collagen than similarly treated 8 mM
gucose-incubated cells, even though the latter demonstrate
no additional increases in glucose transport or GLUT1
expresion.
Although most cell types demonstrate marked down-
regulation of GLUT1 expression when exposed to high
glucose concentrations [57, 65–67], MCs showed only a
nonsignificant decrease in membrane-associated GLUT1
content, despite long-term maintenance in a 20 mM glucose
medium. This result is in contrast to the findings of Heilig
et al, who demonstrated that exposure of MCs to 20 mM
glucose induced a 68% increase in GLUT1 protein [68].
This apparent discrepancy is likely explained by differences
in GLUT1 distribution. In the present study, GLUT1 was
measured in isolated membranes, however, Heilig et al
measured transporter content in whole cell lysates. In any
case, the MCs maintained in a high glucose concentration
showed a small, but significant, increase in glucose trans-
port. Theoretically, the lack of significant membrane-asso-
ciated GLUT1 down-regulation may render MCs vulnera-
ble to the metabolic effects of high glucose concentrations.
One such adverse effect would be an exaggeration of ECM
synthesis and its accumulation, as unequivocally demon-
strated in our study and numerous others [3–8].
At relatively low glucose concentrations, tolazamide in-
creased total collagen accumulation in the medium as a
result of heightened synthesis, unmatched by a similar
change in the catabolism of this matrix component. The
magnitude of the changes in collagen metabolism attrib-
uted to tolazamide was similar to that following chronic
exposure to high glucose concentrations. Notably, the
addition of tolazamide to MCs maintained in high glucose
concentration increased the exaggerated collagen synthesis
and its accumulation even further. In addition, although the
amount of collagen deposited in the cell layer was only a
small fraction of the total synthesized, tolazamide also
increased the quantity deposited in the cell layer. The
tolazamide effect on fibronectin production was very simi-
lar to that seen for total collagen. Specifically, fibronectin
accumulated in the culture medium in large quantities in
MCs cultured at low and high glucose concentrations. In
previous studies, we demonstrated that, in addition to
Fig. 8. Effects of metformin on the formation
of fibronectin and collagen by mesangial cells
cultured in 20 mM glucose concentration. The
accumulation of total collagen in the medium
was studied as in Figure 7. In addition, in the
same experiment, the 72 hour formation of
fibronectin was also evaluated according to its
medium concentration. Cultures were exposed
to the amounts of metformin noted during the
last five days of the experiment. Each value
represents the mean 6 SEM of eight samples.
*P 5 0.016 versus 8 mM control. Symbols are:
(M) fibronectin; (o) collagen.
Fig. 9. Effects of medium glucose concentration and exposure to tolaz-
amide on the formation of fibronectin by mesangial cells. The 72 hour
accumulation of fibronectin was quantified in samples of media obtained
from the same experiment presented in Figure 6. Each value represents
the mean 6 SEM of six samples. *P 5 0.034 versus 8 mM control; ‡P ,
0.001 versus own 8 or 20 mM untreated control; §P 5 0.01 versus 20 mM
control; ¶P , 0.001 versus 8 mM-tolazamide treated.
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changes in ECM synthesis, exposure to high glucose con-
centrations or induction of GLUT1 overexpression in MCs
results in cellular hypertrophy [25, 69]. In this study,
tolazamide also resulted in MC hypertrophy, irrespective of
the glucose level. Therefore, tolazamide appears to elicit a
generalized increase in the accumulation of matrix compo-
nents and cell hypertrophy that mimics and magnifies the
metabolic effects of enhanced glucose uptake and high
glucose concentration.
Concomitantly with increased glucose transport, tolaz-
amide exposure also resulted in the stimulation of the
secretion and activation of TGF-b1. Interestingly, this
occurred at relatively low glucose concentrations, suggest-
ing that the enhanced transport, and probably metabolism
of the hexose, was the stimulus for increased TGF-b1
action. However, it is also known that certain growth
factors, including TGF-b1, stimulate glucose uptake and
the expression of GLUT1 [70, 71]. Therefore, it is also
possible that the tolazamide-induced increase in glucose
transport observed in MCs is a consequence of the stimu-
lation of TGF-b1 activity by the sulfonylurea, rather than
the converse. In any event, the data strongly implicates
TGF-b1 action as a mediator in the enhanced collagen
synthesis caused by tolazamide.
Metformin, a biguanide antihyperglycemic agent, may
also increase insulin-stimulated glucose transport, cell
membrane translocation of GLUT1 and total cellular
GLUT1. These effects have been documented in human
skeletal muscle and L6 cells, adipocytes and fibroblasts
[31–33, 35, 36, 72]. The response to this agent is evident
beyond 16 hours of incubation at concentrations of 8 to 200
mM and is characteristically enhanced by high glucose
concentrations [31–33, 36, 72]. In addition, the metformin-
induced changes are maintained, being still present after at
least 16 days of treatment. In this study, MCs exposed to
200 mM metformin for a five-day period did not manifest
changes in glucose transport, membrane-associated
GLUT1 content, total collagen metabolism, or cell growth,
regardless of glucose concentration. Only at 500 mM, a
metformin concentration five- to tenfold higher than ther-
apeutic plasma levels [73], was there a small increment in
MC glucose uptake and fibronectin accumulation. These
results imply that the metabolic effects induced by met-
formin may not be universal for all cell types.
The data presented here do not cast light on the mech-
anism(s) through which sulfonylureas alter MC metabo-
lism. However, substantial progress has recently been made
regarding the elucidation of the mode of action of these
drugs in other cell types. Sulfonylureas are readily capable
of penetrating cell membranes according to their lipid-
solubility characteristics (tolazamide .. glibenclamide)
[74]. Therefore, they may exert their actions at either
membrane-bound or cytosolic loci. At the cell membrane
sulfonylureas act by their interaction with ATP-sensitive
K1 channels (KATP). These channels, present in pancreatic
Fig. 10. Effects of increasing tolazamide
concentrations on the formation of fibronectin
(M) and collagen (p) by mesangial cells. The
accumulation of fibronectin and total collagen
in the medium was quantified in cells cultured
in 8 mM glucose as in Figures 7 and 9. Cultures
were exposed to increasing amounts of
tolazamide during the last five days of the
experiment. Each value represents the mean 6
SEM of six samples.*P , 0.001, ‡P , 0.008, and
§P , 0.003 versus 8 mM control.
Fig. 11. Effect of tolazamide on the mesangial cell production of active
and total TGF-b1. Mesangial cells were grown as in Figure 6 in a medium
containing 8 mM glucose and treated with 1.5 mM tolazamide during the
last five days of culture. Twenty-four hours before the termination of the
experiment, the medium was replaced with a similar one, but containing
1% FCS in place of NuSerum. Active and total TGF-b1 24-hours secretion
was determined in this medium using a mink lung epithelial cell line
bioassay. Values are mean 6 SE, N 5 6. *P , 0.02 versus control; ‡P ,
0.001 versus control. Symbols are: (M) control; (   ) tolazamide.
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b, brain, skeletal muscle, and vascular and non-vascular
smooth muscle cells, play an important role in the control
of cell behavior by linking the cellular metabolic status to
the membrane potential [75, 76]. KATP channels are formed
by the intimate association of an ion channel subunit (an
inwardly rectifying K1 channel, Kir) and a sulfonylurea
receptor (SUR), a member of the transporter superfamily
of ATP-binding cassette proteins [77–80]. Two SURs, have
been identified to date, SUR1 and SUR2. The first is a high
affinity receptor present in pancreatic b cells and likely the
SUR also found in cerebral cortex and smooth muscle cells
[81, 82]. The second, SUR2, a low affinity receptor, was
initially described in heart and skeletal muscle [78], and
exists in two isoforms, SUR2A and SUR2B [80]. SUR2A is
expressed exclusively in mouse heart while SUR2B is
ubiquitously expressed in all tissues, including the kidney.
The presence of a specific isoform in a given tissue may
determine its response to sulfonylureas, since it has been
shown that SUR confers, in part, the ATP sensitivity and
pharmacological characteristics of KATP channels [78].
Within the cell, sulfonylureas may also act at sites indepen-
dent from those in relationship to the KATP channels
described above. This could be related to the presence of
an as yet uncharacterized pool of specific receptors to
which internalized sulfonylureas might bind [83, 84]. Our
recent demonstration of a functional, membrane-associ-
ated SUR2 in MCs suggests its involvement in mediating
the metabolic effects of tolazamide [85].
Many aspects of MC function that had been initially
demonstrated in tissue culture have been duplicated in situ,
including their responses to specific vasoactive agents and
growth factors. From the studies reported herein, it follows
that sulfonylureas may enhance matrix deposition in the
mesangium, thereby triggering and/or accelerating the de-
velopment of glomerulosclerosis in diabetes. In addition,
this adverse effect may occur despite acceptable levels of
glycemia. Surprisingly, there are no studies available on the
effects of sulfonylureas on the progression of diabetic
glomerulosclerosis in animal models. By the same token,
there is a lack of data regarding the influence of these drugs
on the progression of human diabetic renal disease. In the
largest prospective, randomized study available on vascular
disease in type II diabetes, the degree of histological
glomerular disease among individuals in groups receiving
different treatment regimens was not analyzed separately
[84]. Therefore, we conclude that performance of studies
regarding the renal effects of antihyperglycemic agents in
human and animal models of type II diabetes is an imper-
ative.
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